OncoMatch/Clinical Trials/NCT06500234
Nutrition Impact on Immunotherapy of Cancer
Is NCT06500234 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Megestrol Acetate and olanzapine and Starch powder 50 mg for nutrition disorders.
Treatment: Megestrol Acetate and olanzapine · Starch powder 50 mg — This study investigates nutritional status and outcomes of immuntherapy in cancer patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Kidney function
normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Liver function
normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06500234 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify